Research Article
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4+ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
Table 1
Characteristics of patients and healthy volunteers (HVs).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
na: not applicable. *Untreated RRMS patients are older than HVs (n.s.) and natalizumab (Nat.) treated patients (). **At the sampling time. ***Before natalizumab (Nat.) treatment. |